...Kamada and myTomorrows launched an early access program (EAP) in Europe for Kamada’s highly purified alpha-1...
...GvHD). The product is IV human plasma. Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA), Ness Ziona, Israel myTomorrows...

...the drugs, and there are no requirements for monitoring outcomes, he reported. myTomorrows Another company, myTomorrows...
...an "honest broker" between pharmaceutical companies and physicians and patients, according to CEO Ronald Brus. myTomorrows...
...in May that myTomorrows will make multiple sclerosis (MS) candidate ATL1102 available in the EU. myTomorrows...

...Hemispherx and myTomorrows launched Hemispherx’s Ampligen rintatolimod through an early access program in Europe and Turkey...
...has Orphan Drug designation in Europe to treat Ebola. Hemispherx Biopharma Inc. (NYSE-M:HEB), Philadelphia, Pa. myTomorrows...

...Switzerland and Turkey, was originally available to recurrent chest wall breast cancer patients. Celsion said myTomorrows...
...half. ThermoDox is doxorubicin encapsulated in a heat-activated liposome. Celsion Corp. , (NASDAQ:CLSN), Lawrenceville, N.J. myTomorrows...

...Public Policy at the National Organization for Rare Disorders (NORD); and Sjaak Vink, CEO of myTomorrows...

...Online patient platform myTomorrows will offer patients access to DanDrit's MelCancerVac and to an undisclosed therapeutic...
...has completed Phase II testing to treat colorectal cancer and non-small cell lung cancer (NSCLC). myTomorrows...
...vaccine specifics. myTomorrows said Oxford BioMedica's vaccine will be available worldwide upon request by doctors. myTomorrows...

...On Dec. 20, 2013, Syntropharma said online patient platform myTomorrows (Amsterdam, the Netherlands) will offer patients...
...access to Selegiline Transdermal System, which is in development to treat major depressive disorder (MDD). myTomorrows...
...will make the product available in the Netherlands, Belgium, Luxembourg, France, Italy, Germany and Turkey. myTomorrows...